Heat shock protein 90 (HSP90) is a molecular chaperone that supervises folding of cellular signaling proteins such as steroid receptors and many protein kinases. HSP90 relies on ATP hydrolysis for powering a conformational circuit that helps fold the client protein. To that end, HSP90 binds to co-chaperone proteins that regulate ATP hydrolysis rate or interaction with client proteins. Co-chaperones such as P23, cell division cycle 37 (CDC37), or activator of HSP90 ATPase activity 1 (AHA1) interact with the N-terminal or middle domain of HSP90, whereas others, such as HSP70/HSP90-organizing protein (HOP), use tetratricopeptide repeat (TPR) domains to bind the EEVD motif at the very C-terminal end of HSP90. Recently, the lysine methyltransferase SET and MYND domain-containing 2 (SMYD2) has been proposed as an HSP90-binding partner, and interaction analyses indicate that SMYD2 binding to HSP90 is independent of the EEVD motif. Using the amplified luminescence proximity homogeneous assay (Alpha) technique, I identified a new (M/I/L/V)PXL motif at the C termini of HSP90 and P23 that mediates an interaction with SMYD2, and synthetic peptides harboring this motif dissociated this complex. Of note, the HSP90-and P23-dependent client estrogen receptor ␣ (ER␣), was a major methylation target of SMYD2. In a reconstituted system in bacteria, I analyzed HSP90/P23-associated, SMYD2mediated ER␣ methylation and found that when SMYD2 binds to the molecular chaperones, it considerably increases methylation of Lys-266 in ER␣. Because methylation represses ER␣ activity, the observed complex formation between SMYD2 and HSP90/P23 may contribute to ER␣ regulation.
HSP90 is a major molecular chaperone in the eukaryotic cytosol that oversees folding and degradation of a subset of client proteins and therefore contributes to cellular protein homeostasis. The HSP90 client spectrum ranges from steroid hormone receptors (e.g. glucocorticoid receptor, progesterone receptor, and estrogen receptor) and protein kinases (e.g. SRC, CDK4, and AKT) to transcription factors (e.g. OCT4 or P53 tumor suppressor) and others such as cystic fibrosis transmem-brane conductance regulator or Tau protein (1) . Many client proteins, when mutated or deregulated, are related to wellknown diseases such as various cancer types, cystic fibrosis, and neurodegenerative disorders (1) (2) (3) . HSP90 function depends on ATP hydrolysis that drives a conformational cycle during which the protein client either folds or is triaged for proteolytic degradation (4 -6) . To fulfill its tasks, HSP90 is assisted by a multitude of cochaperone proteins that modulate its ATP hydrolysis rate or mediate the interaction with client proteins. Some cochaperones, such as P23, CDC37, or AHA1, interact with the N-terminal domain or the middle domain of the molecular chaperone (6) . Others, such as HOP, CHIP, DNAJC7, PP5 (protein phosphatase 5), and the immunophilins, use tetratricopeptide repeat (TPR) 2 domains to clamp the C-terminal EEVD motif of HSP90 for interaction (7) (8) (9) .
SMYD2 was initially identified as a histone H3-specific lysine methyltransferase that interacted with HSP90 (10, 11) . Histone methylation activity suggested a role for SMYD2 as regulator of gene expression. Shortly after, additional nonhistone methylation targets of SMYD2 were reported, including the transcription factors tumor suppressor P53 and estrogen receptor ␣ (ER␣) and the molecular chaperone HSP90 (12) (13) (14) . SMYD2-catalyzed methylation reduces P53 and ER␣ transcriptional activity and therefore represses P53 and ER␣ target gene expression (12, 14) . Crystal structures of SMYD2 in complex with histone, P53, and ER␣ target peptides were solved (15) (16) (17) (18) . Accordingly, SMYD2 consists of an N-terminal catalytic domain (N-lobe) and a C-terminal domain (C-lobe) with structural similarity to the TPR domains of cochaperone proteins that bind to the EEVD motif of HSP90. Therefore, it was proposed that the C-lobe of SMYD2 may bind to HSP90 in a manner similar to the TPR clamp mechanism of HSP90 cochaperones, such as HOP (15) . However, this hypothesis was never tested experimentally. Moreover, the purpose of the SMYD2-HSP90 interaction remains elusive, although one may speculate that the molecular chaperone may affect SMYD2 target protein methylation.
In the present study, binding of SMYD2 to HSP90 and HOP to HSP90 was compared and found to be fundamentally differ-ent. Whereas HOP interaction required the C-terminal EEVD motif of HSP90, this sequence was dispensable for SMYD2 binding. Using Alpha (amplified luminescence proximity homogeneous assay) for interaction analysis, an (M/I/L/V)PXL motif, present in HSP90 and in the cochaperone P23, was identified as the binding site for SMYD2. When SMYD2-catalyzed lysine methylation of P53, ER␣, and HSP90 was compared, ER␣ turned out to be the major target. The HSP90/P23-dependent client protein ER␣ was used to investigate the functional role of HSP90/P23-SMYD2 complex formation. To that purpose, an HSP90/P23-chaperoned ER␣ expression system was reconstituted. Efficient lysine methylation of ER␣ depended on interaction between SMYD2 and the molecular chaperones HSP90/ P23. This suggests that the molecular chaperone-SMYD2 alliance may keep ER␣ in an inactive methylated state during folding, before activation by estrogen. Accordingly, HSP90/P23 contribute to another layer of ER␣ regulation by SMYD2-dependent methylation.
Results

SMYD2 binds to HSP90 independently of the C-terminal EEVD motif and to the cochaperone P23
Previous studies reported that SMYD2 binds to the molecular chaperone HSP90 in human culture cells (11, 13) . To test this observation, SMYD2 and HOP were mixed with HSP90␣, and the interaction was analyzed by gel filtration chromatography (19 -21) . A shift of the SMYD2 elution profile and co-migration together with HSP90␣ indicated complex formation between the two proteins, independent of nucleotide ( Fig. 1A) . Likewise, SMYD2 bound to HSP90␤ indistinguishably from HSP90␣ ( Fig. 1A) .
It was proposed that the C-lobe of SMYD2 is a TPR-like domain and binds to HSP90 dependent on the EEVD motif, similar to cochaperone proteins such as HOP or DNAJC7 (7, 8) . However, alignment of the SMYD2 C-lobe sequence with bona fide TPR domains of HSP90 binding partners revealed that A, SMYD2 and HOP were incubated with HSP90␣, HSP90␣⌬EEVD, or HSP90␤ and analyzed by gel filtration chromatography. A shift of SMYD2 and HOP together with HSP90␣, HSP90␣⌬EEVD, or HSP90␤ toward higher molecular weight indicates the formation of robust protein complexes (indicated by red and blue dashed boxes). Marker proteins (thyroglobulin (669 kDa) and BSA (67 kDa)) are shown on top. SMYD2 binds to HSP90␣ and HSP90␤, independent from the EEVD motif at the C terminus of the molecular chaperone, in contrast to the cochaperone HOP. The interaction between SMYD2 and HSP90␣ is insensitive to ATP␥S. B, the C-terminal domain HSP90␣C is sufficient for interaction to SMYD2. Shifts of SMYD2 and HSP90␣C are indicated by red and black dashed boxes. C, SMYD2N-lobe, the catalytic domain of SMYD2, interacts with HSP90␣, as indicated by a dashed red box. D, SMYD2 binds to the HSP90 cochaperone P23. Shifts of SMYD2 and P23 are indicated by red and green dashed boxes. E, compilation of the protein-protein interaction results. F, summary model of SMYD2-HSP90 and SMYD2-P23 binary protein complexes. Marker proteins are indicated in kDa.
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amino acid residues of the dicarboxylate clamp responsible for EEVD interaction are not conserved in SMYD2 (Fig. S1 ). This suggests that the EEVD motif is dispensable for interaction with SMYD2. To test this assumption, the EEVD motif of HSP90␣ was cleaved off, and the truncated protein (HSP90␣⌬ EEVD) was analyzed for complex formation with SMYD2 and HOP ( Fig. 1A) . Whereas HSP90␣⌬EEVD showed no interaction with HOP as expected, SMYD2 binding to HSP90␣ did not require the EEVD motif ( Fig. 1A) , although SMYD2 binding was mediated by HSP90␣C ( Fig. 1B ). This suggests that SMYD2, in contrast to HOP, does not use the TPR clamp mechanism for interaction with HSP90. Furthermore, the catalytic SMYD2Nlobe was sufficient for interaction with HSP90␣ ( Fig. 1C ). To determine whether SMYD2 forms complexes with yet unidentified partners, the methyltransferase was applied as bait in a yeast two-hybrid screen using a universal human library. Hits identified were fragments encompassing amino acids 697-732 in the C terminus of HSP90␣, confirming the result shown in Fig. 1B , and amino acids 110 -160, representing a C-terminal fragment of the HSP90 cochaperone P23 ( Fig. S2 ). Interaction between SMYD2 and P23 was confirmed by gel filtration chromatography using the purified proteins ( Fig. 1D ). The results of the protein interaction analysis are compiled in Fig. 1E . In summary, SMYD2 forms complexes with both chaperone partners HSP90 and P23 ( Fig. 1F ).
A new (M/I/L/V)PXL motif at the C termini of HSP90 and P23 connects the molecular chaperones to SMYD2
Based on the result of the yeast two-hybrid screen, the binding site between SMYD2 and HSP90␣ could be mapped to a C-terminal fragment of the molecular chaperone comprising amino acids 697-732, consistent with the biochemical data ( Fig. 1B ). Alpha technology (22) was used to further explore the interaction between SMYD2 and the HSP90 polypeptide ( Fig.  2A ). Candidate proteins are attached to GST donor beads or nickel-chelate acceptor beads and brought to close proximity upon protein interaction. Laser excitation leads to emittance of singlet oxygen from donor beads and triggers emission of luminescence by acceptor beads that can be quantified. Mutant proteins or the addition of inhibitors prevent interactiondependent excitation of acceptor beads ( Fig. 2A) . A variety of GST-HSP90␣ fusion peptides and His 6 -tagged SMYD2 or SMYD2N proteins were purified and analyzed for interaction ( Fig. S3 and Table S1 ). Full-length HSP90, HSP90C, and HSP90(697-732) bound to SMYD2, whereas HSP90(1-696) did not ( Fig. 2B ). Subsequently, HSP90(697-732) was trimmed at both termini, and the GST-fused fragments were tested for binding to SMYD2. Eventually, the nonapeptide EMPPLEGDD (HSP90(715-723)) was identified to be sufficient for interaction with SMYD2 ( Fig. 2B ). In an effort to locate the peptide binding site on SMYD2, the smallest protein that could be stably expressed was SMYD2(1-240). This fragment bound to HSP90(715-723) equally well as full-length SMYD2 (Fig. 2C ). Next, the sequence motif essential for HSP90␣-SMYD2 complex formation should be identified. Therefore, peptide EMPPLEGDD was subjected to iterative rounds of amino acid substitutions, and the mutant peptides were purified and analyzed for interaction with SMYD2 by Alpha ( Fig. S4 and Table S2 ). It turned out that the motif (M/I/L/V)PXL, where Met could be substituted with amino acid Ile, Leu, or Val and X could be any amino acid in HSP90␣, was essential for binding to SMYD2 (Fig. 2D ). The corresponding sequence in HSP90␤ is IPPL, consistent with this finding (Fig. 2D ). To further corroborate the (M/I/L/V)PXL motif as the SMYD2-binding site, the essential proline was substituted by an alanine, leading to HSP90␣P717A, and the full-length protein was purified. After the addition of SMYD2 or HOP, complex formation was analyzed by gel filtration chromatography (Fig. 2E ). The P717A mutation starkly affected binding to SMYD2 but did not alter interaction with HOP, confirming the specificity of the (M/I/L/V)PXL motif for SMYD2.
Another binding partner of SMYD2 is the cochaperone P23, and the interaction of the fragment P23(110 -160) with the methyltransferase could be verified by Alpha based on GSTtagged P23 proteins ( Fig. S5A and Table S3 ). Sequence alignment using the HSP90␣ peptide revealed the presence of an (M/I/L/V)PXL motif at the very C terminus of P23, suggesting that this piece is responsible for P23-SMYD2 complex formation ( Fig. 2F ). Mutation of each of the amino acids Met-156, Pro-158, and Leu-159 in Pro-23 to alanine completely abolished binding of P23 to SMYD2, confirming that the cochaperone uses its very C-terminal end for interaction with the methyltransferase ( Fig. S5A and Table S3 ). To test whether SMYD2 binds to other GST-tagged chaperone proteins, a C-terminal part of Hsc70 (Hsc70C), HOP, and AHA1 were purified and analyzed by Alpha ( Fig. S5B ). Neither Hsc70C nor any of the cochaperones bound to the methyltransferase (Table S3 ). Several cochaperone proteins compete with each other for binding to HSP90, although they employ different sites on the molecular chaperone for interaction (19, 23) . Therefore, HSP90-HOP and HSP90-AHA1 were incubated with SMYD2, and complex dissociation was analyzed. Although HOP and AHA1 use a binding motif or interaction site different from SMYD2, the methyltransferase disturbs complex formation with HSP90, suggesting steric overlap between SMYD2 and the cochaperones HOP and AHA1 (Fig. 2G ).
The HSP90/P23-dependent client ER␣ is a major methylation target of SMYD2
SMYD2 was originally described as a histone H3 lysine 36 -specific methyltransferase (10) . Shortly after, several nonhistone target proteins were reported, among them the tumor suppressor P53 (12), the molecular chaperone HSP90 (13) , and ER␣ (14) . To obtain insight into the target-specific methylation activity of SMYD2, 36-mer peptides of P53, HSP90␣, and ER␣ containing the proposed methylation sequences were produced as GST fusions. For comparability, target lysines were at the same position within each sequence, using the P53(358 -393) peptide as a blueprint (17) (Fig. 3A) . GST alone and His 6 -HSP90(544 -732) served as controls. After incubation with SMYD2, lysine methylation was detected with two different specific antibodies. Relative signal intensity was strongest with ER␣(254 -289), considerably weaker with P53(358 -393), and invisible with HSP90␣(603-638) or His 6 -HSP90(544 -732), suggesting that ER␣ is a major SMYD2 methylation target (Fig.  3B ). To ensure that Lys-266 is indeed the SMYD2-dependent
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methylation target in ER␣(254 -289), mutants K266A and K266R were tested, and both abolished the lysine methylation signal (Fig. 3C ). SMYD2 catalytic activity toward P53 can be inhibited by LLY-507, a chemical compound that is specific for this methyltransferase (24) . Thus, we tested methylation of the target peptide ER␣(254 -289) in the presence of LLY-507 ( Fig.  3D ). As a result, SMYD2-catalyzed ER␣(254 -289) methylation was disturbed by LLY-507 in a concentration-dependent manner.
SMYD2 recruitment by the (M/I/L/V)PXL motif in HSP90 and P23 results in efficient methylation of ER␣ at Lys-266
The next aim was to examine the effect of (M/I/L/V)PXLmediated SMYD2-chaperone association on the methylation status of ER␣. Identification of this motif allowed synthesis of short peptides derived from HSP90␣ and P23 that contain the SMYD2-binding sequence. Accordingly, peptides HSP90(707-723) spanning the amino acid sequence DTSAAVTEEMP-PLEGDD and P23(147-160) spanning the sequence DSQDSD- (Table S1 ). C, SMYD2N-lobe, the catalytic domain of SMYD2, is sufficient for interaction with HSP90 (Table S1 ). D, mutation of the EMPPLEGDD peptide sequence identified (M/I/L/V)PXL as the SMYD2 interaction motif in HSP90␣. Binding between mutant GST fusion peptides and SMYD2 was measured by Alpha assay (Table S2 ). Alignment of respective HSP90␣ and HSP90␤ sequences shows the conservative exchange of Met to Ile in HSP90␤. E, the HSP90 mutant P717A interacts with HOP but not with SMYD2, consistent with the presence (black) or absence (orange) of a protein shift together with HSP90, as revealed by gel filtration analysis. F, the EMPPLE sequence of HSP90␣ matches with the very C-terminal amino acids in P23, disclosing the (M/I/L/V)PXL motif in the cochaperone indicated by a black box. Mutational analysis confirms P23 as a SMYD2-binding protein (Table S3 ). G, SMYD2 competes with HOP and AHA1 for complex formation with HSP90. Although SMYD2, HOP, and AHA1 use different motifs or sites for interaction, HSP90 allows only binary complexes with each of the three proteins, suggesting that steric requirements hinder binding of more than one protein to the molecular chaperone. Marker proteins are indicated in kDa. Error bars, S.D.
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DEKMPDLE were made. To test the potency of the peptides to interfere with binding, HSP90␣-SMYD2 and P23-SMYD2 protein complexes were incubated with various concentrations of the peptides, and dissociation was measured by Alpha (Fig. 4A ). 90C12mer (GDDDTSRMEEVD), a peptide that dis-turbs binding of TPR proteins to HSP90 (7, 8) and methylation cofactor S-adenosylmethionine (SAM) served as controls. HSP90(707-723) and P23(147-160) readily abrogated formation of homologous HSP90␣-SMYD2 and P23-SMYD2 complexes with an IC 50 in the low micromolar range (Fig. 4A ). In the Figure 3 . ER␣ is a major methylation target of SMYD2. A, 36-mer GST fusion sequences of ER␣, HSP90␣, and P53 used for methylation by SMYD2. The lysine residue supposed to be the methylation target is indicated in red. B, relative methylation of ER␣, HSP90␣, and P53 by SMYD2. ER␣ is a major and P53 is a minor methylation target of SMYD2, as detected by independent blotting with lysine methylation-specific antibodies ADI-KAP-TF121 (Enzo) and SPC-158F (Stress-Marq). GST-HSP90␣(603-638) and His 6 -HSP90␣(544 -732) showed no detectable methylation signal when tested together with ER␣ and P53. GST served as a negative control, and protein loading was monitored by subsequent blotting with anti-GST or anti-His 6 antibody and by Coomassie staining of an identical gel. C, Lys-266 in ER␣ is the methylation target of SMYD2. Mutants K266A and K266R are no longer methylated by SMYD2. A GST loading control is shown below. D, methylation of GST-ER␣(254 -289) is prevented by the SMYD2 inhibitor LLY-507 in a concentration-dependent manner. A GST loading control is shown below. E, peptides HSP90(707-723), P23(147-160), and 90C12mer do not affect SMYD2-dependent methylation of ER␣(254 -289) when used at 200 M, in contrast to the SMYD2 inhibitor LLY-507. A GST loading control is shown below. Relative methylation levels of ER␣(254 -289) are indicated, with S.D. indicated by error bars. Marker proteins are indicated in kDa.
heterologous situation, P23(147-160) was even more efficient toward HSP90␣-SMYD2 than HSP90(707-723), but toward the P23-SMYD2 complex, HSP90(707-723) was ϳ10-fold less effective compared with P23(147-160). Given that the (M/I/L/ V)PXL motif sits at the very end of P23 but is flanked by C-terminal amino acids in HSP90, P23 might be accommodated more readily by SMYD2, resulting in higher binding affinity. To confirm the results obtained by Alpha, HSP90␣ and SMYD2 were mixed; incubated with peptide HSP90(707-723), P23(147-160), 90C12mer, or LLY-507; and analyzed for interaction by gel filtration chromatography (Fig. S6 ). HSP90(707-723) and P23(147-160) but neither 90C12mer nor LLY-507 dissociated HSP90 -SMYD2 complexes.
To set up a test system to explore the effect of (M/I/L/V)PXLmediated SMYD2-chaperone association on the methylation status of ER␣, the hormone receptor should be expressed alone or together with chaperones HSP90␣ and P23 and methylated by SMYD2. Therefore, ER␣(254 -595) was cloned as a GST fusion protein. This fragment contains the hinge region of ER␣ with the SMYD2 methylation target Lys-266 and the C-terminal part of the receptor that harbors the ligand binding domain and associates with HSP90 and P23 (25-28) (Fig. 4D ). HSP90 The SMYD2 inhibitor LLY-507 inhibits methylation completely, whereas peptide 90C12mer has no effect on ER␣K266 methylation. All compounds were added at 200 M. D, illustration of SMYD2 dependent methylation of Lys-266 in the hinge region of ER␣ in the presence of molecular chaperones HSP90 and P23. It is not intended to propose stoichiometry of the protein components. Marker proteins are indicated in kDa.
and P23 were cloned into a bicistronic vector for joint expression (see "Experimental procedures"). Accordingly, GST-ER␣(254 -595) was expressed together with HSP90 and P23 or in their absence (Fig. 4B ). HSP90/P23 markedly increased the expression level of GST-ER␣(254 -595). Gel filtration analysis showed that GST-ER␣(254 -595) is retained when expressed together with HSP90 and P23, suggesting that the molecular chaperones associate with the steroid receptor and prevent its aggregation (Fig. S7) . Moreover, SMYD2-dependent methylation of GST-ER␣(254 -595) was higher in the presence of HSP90 and P23 (Fig. 4B ). This indicates that the chaperones hold GST-ER␣(254 -595) competent for methylation and/or recruit SMYD2. To analyze this further, peptides HSP90(707-723) and P23(147-160) should be used to block the interaction between the chaperones and SMYD2 to measure methylation of GST-ER␣(254 -595) in the absence of HSP90␣-SMYD2 and P23-SMYD2 complexes. To rule out any adverse effect of HSP90(707-723) and P23(147-160) on the catalytic activity of SMYD2, methylation of GST-ER␣(254 -289) was assayed in the presence of the peptides using LLY-507 and 90C12mer as controls ( Fig. 3E ). HSP90(707-723) and P23(147-160) did not affect the catalytic activity of SMYD2 at 200 M, the concentration used for the following assay (Fig. 3E) . To test the effect of HSP90 -SMYD2 and P23-SMYD2 complex formation on ER␣ Lys-266 (ER␣K266) methylation, the assay was performed in the presence of HSP90(707-723) and P23(147-160) to disturb SMYD2 recruitment by the chaperones using LLY-507 and 90C12mer as controls. Complex dissociation by HSP90(707-723) and P23(147-160) peptides resulted in a decrease of GST-ER␣(254 -289) Lys-266 methylation to about one-third of control (Fig. 4C ). This provides evidence that the (M/I/L/V)PXL motif recruits SMYD2 to HSP90/P23 for efficient methylation of the chaperone-associated client protein ER␣ at Lys-266 ( Fig. 4D ).
Discussion
The present study shows that the lysine methyltransferase SMYD2 binds to the C-terminal domain of HSP90, yet independent of the EEVD motif that is used by TPR domain cochaperones such as HOP for interaction (7, 8) . In lieu thereof, a new (M/I/L/V)PXL binding motif present at the C termini of the molecular chaperones HSP90 and P23 mediates complex formation with SMYD2. Although SMYD2 uses this unique sequence for HSP90 binding, it competes with HOP and the HSP90 ATPase activator AHA1 for interaction with the molecular chaperone. This suggests that SMYD2 may add another layer of regulation to HSP90-dependent client protein activation, apart from the established functions that are performed by cochaperones such as AHA1 and HOP. To further dissect the roleofHSP90 -SMYD2complexformation,relativelysinemethylation of nonhistone SMYD2 target proteins was measured. This analysis revealed Lys-266 in the hinge region of ER␣ as a major methylation target of SMYD2, when compared with previously reported proteins such as P53 or HSP90. ER␣ belongs to the steroid receptor family and is a bona fide HSP90/P23-dependent client protein. Therefore, an HSP90/P23-chaperoned ER␣ expression system was reconstituted to decipher the role of SMYD2-chaperone com-plexes toward estrogen receptor ␣ methylation. This expression system indicated that the amount of soluble ER␣ protein produced was contingent on HSP90/P23, approving the significance of the molecular chaperones for client protein folding and prevention of aggregation.
Furthermore, SMYD2-catalyzed methylation of ER␣ was considerably higher in the presence of the molecular chaperones HSP90 and P23. In contrast, dissociation of SMYD2 from the molecular chaperones HSP90/P23 by interfering with synthetic peptides considerably reduced ER␣K266 methylation, suggesting that SMYD2-chaperone complexes are required for efficient methylation of ER␣. This finding raises the question of the purpose of SMYD2-associated methylation of the HSP90/ P23-dependent client protein ER␣. SMYD2-catalyzed methylation puts an inhibitory mark on ER␣K266 and P53 Lys-370, prevents binding of these transcription factors to their respective promoters on the DNA, and thereby prevents their gene expression activity (12, 14) . Because P53 promotes apoptosis of cancer cells, lysine methyltransferase SMYD2 that inactivates this tumor suppressor may be considered a cancer-promoting oncogene (12) . Following the standard model of steroid receptor activation, HSP90 interacts with ER␣ to keep the receptor in an inactive folding-competent state (29, 30) . Accordingly, in the absence of activating hormone estrogen, methylation of the hinge region at Lys-266 by SMYD2 in the presence of HSP90/ P23 may prevent premature dimerization and coactivator binding of ER␣ and allow proper chaperone-assisted folding of this steroid receptor. Upon estrogen binding, however, the chaperones HSP90/P23 are released from ER␣ together with SMYD2, resulting in lower Lys-266 methylation and receptor activation. The methylation mark on ER␣K266 and P53 Lys-370 is a reversible modification and can be removed by LSD1, a lysinespecific demethylase (14, 16, 31) , which is associated with ER␣ and P53 activation. As a consequence, demethylated ER␣K266 gains transcriptional activity.
In an alternative model that has been proposed recently, ER␣ is engaged in coregulator complexes together with HSP90, where the molecular chaperone may act as a scaffold (32) . In such an ensemble, it is conceivable that HSP90-dependent SMYD2 recruitment leads to methylation and deactivation of ER␣. In turn, LSD1-mediated demethylation would activate ER␣. This balance of methylation/demethylation events may add a layer of regulation to ER␣ activity that is, in part, brought about by the molecular chaperones HSP90 and P23.
Experimental procedures
Antibodies, peptides, and chemicals
Mouse monoclonal antibodies specific for GST tag and His 6 tag were from Abcam; P23 mouse mAb JJ3 was from Thermo Fisher Scientific; rabbit polyclonal anti-methylated lysine antibodies ADI-KAP-TF121 and SPC-158F were from Enzo Life Sciences and StressMarq Biosciences, respectively; and rabbit polyclonal anti-ER␣K266Me antibody was a kind gift from Xiaobing Shi. Synthetic peptides HSP90(707-723), P23(147-160), and 90C12mer were from Metabion International, and SMYD2 inhibitor LLY-507 was from Sigma.
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Expression constructs and recombinant protein purification SMYD2 constructs were amplified from a human skeletal muscle first-strand cDNA preparation (Clontech) and cloned into His 6 -tagged pProExHta expression vector. P53(358 -393) was amplified from a human placenta first-strand cDNA preparation (Clontech) and cloned into GST fusion expression vector pGEX-4T1. ER␣(254 -289) and ER␣(254 -595) were amplified from IMAGE cDNA clone IRCMp5012F0638D (Source Bioscience) and cloned into GST fusion expression vector pGEX-4T1. HSP90, HOP, P23, and AHA1 expression vectors were described earlier (4, 21, 22) . HSP90 and P23 fragments were expressed as GST fusion proteins from vector pGEX-4T1. Point mutations in expression constructs were generated with the QuikChange site-directed mutagenesis kit (Stratagene) using missense oligonucleotides. For expression of GST-ER␣(254 -595) from pGEX-4T1 in the presence of chaperones, a dicistronic pET28b expression vector was constructed containing P23 and His 6 -HSP90␣ in series following the EMBL dicistronic cloning protocol (https://www.embl.de/pepcore/ pepcore_services/cloning/cloning_methods/dicistronic_cloning/ index.html). 3 All clones were verified by DNA sequencing. ER␣ and HSP90/P23 vectors were co-transformed into Escherichia coli following selection on ampicillin-and kanamycin-containing medium, with empty pET28b vector serving as control. Recombinant proteins were expressed in E. coli BL21(DE3)pLysS as GST and His 6 fusions and purified using GSH-Sepharose 4B (GE Healthcare) or nickel-chelate agarose (Qiagen) affinity beads. Further purification was performed by gel filtration chromatography on a Superose 12 HR10/30 column or by ionexchange chromatography on a ResourceQ column using an ÄktaPurifier system (GE Healthcare).
Protein interaction analysis by gel filtration chromatography
Each 5 M concentration of purified proteins was mixed and incubated at room temperature for 10 min and on ice for another 10 min to allow complex formation. 500-l samples were separated on a Superose 12 HR10/30 column in 40 mM HEPES/KOH buffer (pH 7.4), 50 mM KCl, 2 mM MgCl 2 operated by an ÄktaPurifier system (GE Healthcare). 500-l fractions were collected after a 6-ml elution volume and analyzed by SDS-PAGE. When bacterial cell lysates were examined by chromatography, proteins were visualized by Western blotting with specific antibodies after SDS-PAGE.
Alpha assay
Purified protein interaction partners with N-terminal GST or His 6 tags were incubated in 40 mM HEPES, pH 7.4, 50 mM KCl, 2 mM MgCl 2 , 0.5% BSA for 10 min at 30°C, followed by 10 min at 4°C. Control reactions contained GST only together with the His 6 tag partner protein. Donor and acceptor beads (4 g/ml) were added to protein complexes at a final concentration of 0.3 M and further incubated at room temperature for 40 min in an AlphaPlate-384 (PerkinElmer Life Sciences). Luminescence signals were measured in an EnSpire Multimode Plate Reader (PerkinElmer Life Sciences). For competition studies, interaction partners were incubated in the presence of competing synthetic peptides or competing proteins without tags at various concentrations as indicated. Experiments were performed in triplicate, and IC 50 values were determined after data fitting to a four-parameter logistic curve equation using Sigma-Plot software.
Yeast two-hybrid screen
Yeast two-hybrid screening was essentially done as described previously (23) . Human SMYD2 was cloned into vector pGBKT7 and transformed into the Y2HGold reporter strain (Clontech). Cells were mated with strain Y187 pretransformed with a Universal Human (Normalized) Mate & Plate Library in vector pACT2 (Clontech). After selection for protein-protein interactions on SD/ϪLeu/ϪTrp/ϪHis plates by growth and blue staining on SD/ϪLeu/ϪTrp ϩ X-␣-Gal medium, DNA was isolated from yeast cells and transformed into E. coli XL-1 blue, and pACT2 plasmids were isolated for sequencing of the prey inserts.
Methylation assay
Fusion protein GST-ER␣(254 -289), GST-HSP90␣(603-638), GST-P53(358 -393), or His 6 -HSP90␣(544 -732) (3 M) was incubated with 2 M SMYD2 and 200 M SAM for 1 h at 30°C in 50 mM Tris, pH 9.0, 2 mM MgCl 2 . Methylation was analyzed by blotting with anti-methylated lysine antibodies ADI-KAP-TF121 and SPC-158F. Subsequent blotting with anti-GST-or anti-His 6 -specific antibodies was used for loading controls. When indicated, LLY-507 or peptides HSP90(707-723), P23(147-160), and 90C12mer were added at concentrations up to 200 M to GST-ER␣(254 -289) methylation assays. For analysis of HSP90/P23-associated SMYD2 methylation, GST-ER␣(254 -595) was expressed alone or together with the chaperones in E. coli and the cell lysate used in the assay as described above in the presence or absence of methylation inhibitor LLY-507, peptides HSP90(707-723), P23(147-160), or 90C12mer as a control at 200 M. Sequence-specific methylation of ER␣(254 -595) was assayed with anti-ER␣K266Me antibody. Experiments were repeated at least three times, and quantification of methylation signals was done with ImageJ software. 
